The competitive dynamics within the lucrative anti-obesity medication sector shifted this week, marked by two pivotal developments from key players. Novo Nordisk secured a significant expansion in Europe, while rival Eli Lilly launched a direct challenge in the United States with a new, lower-cost oral treatment. These simultaneous moves underscore the intensifying, multi-front competition in the GLP-1 agonist market.
Strategic Expansion for Novo Nordisk in the UK
Novo Nordisk achieved a major regulatory win that broadens the clinical and commercial profile of its drug, Wegovy. The UK’s National Institute for Health and Care Excellence (NICE) has issued a recommendation for the medication to be used for preventing cardiovascular events. This decision opens access within the National Health Service (NHS) for an estimated 1.2 million additional patients.
The recommendation specifically targets the prevention of heart attacks and strokes in individuals with a prior history of cardiovascular disease and a Body Mass Index (BMI) of 27 or higher. Crucially, clinical evidence indicates that this protective effect occurs even before patients experience substantial weight loss. This new medical indication allows Novo Nordisk to position Wegovy beyond the pure lifestyle and weight-management segment, anchoring it firmly in cardiovascular risk reduction.
Eli Lilly Launches Aggressive Price Challenge
Concurrently, Eli Lilly introduced a new competitive threat with the accelerated approval by the U.S. Food and Drug Administration (FDA) for its daily tablet, Foundayo. The oral therapy directly targets a patient population currently dominated by injectable treatments, with pricing being a central part of its strategy.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Priced between $149 and $349 per month for cash-paying patients, Foundayo is positioned as a more accessible alternative. Clinical trial data supports an average weight reduction of approximately 11% over a 72-week period. The company plans a rapid commercial rollout, beginning direct-to-consumer shipments on Monday, followed by distribution through pharmacies and telemedicine providers. This aggressive market entry is expected to immediately increase pricing pressure on established market leaders, including Novo Nordisk.
Innovation Beyond Drug Therapy
Beyond the direct pharmaceutical rivalry, the market is also seeing the emergence of novel, complementary treatment approaches. Fractyl Health is developing an endoscopic procedure called Revita, designed to address weight regain after patients discontinue GLP-1 medications.
Preliminary pilot study results suggest the procedure may help mitigate post-treatment weight rebound. Definitive data from the ongoing REMAIN-1 study is anticipated in the fourth quarter of 2026, which will inform the next steps for long-term obesity care management following drug therapy. This highlights the sector’s evolution toward addressing the entire patient journey.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from April 4 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 4.
Novo Nordisk: Buy or sell? Read more here...
